Article
Horizontal Combination of MEK and PI3K/mTOR Inhibition in BRAF Mutant Tumor Cells with or without Concomitant PI3K Pathway Mutations.
International journal of molecular sciences - 16 Oct 2020
Rittler Dominika, Molnár Eszter, Baranyi Marcell, Garay Tamás, Hegedűs Luca, Aigner Clemens, Tóvári József, Tímár József, Hegedűs Balázs
Abstract excerpt
The RAS/RAF and PI3K/Akt pathways play a key regulatory role in cancer and are often hit by oncogenic mutations. Despite molecular targeting, the long-term success of monotherapy is often hampered by de novo or acquired resistance. In the case of concurrent mutations in both pathways, horizontal combination could be a reasonable approach. In our study, we investigated the MEK inhibitor selumetinib and PI3K/mTOR...
Topics
- Animals
- Antineoplastic Agents
- Benzimidazoles
- Cell Line, Tumor
- Drug Resistance, Neoplasm
- Female
- Humans
- Imidazoles
- MAP Kinase Kinase Kinases
- Melanoma